TABLE 3. Effectiveness of 2024–2025 COVID-19 vaccination against COVID-19–associated hospitalization among adults aged ≥65 years — VISION and IVY Networks, September 2024–January 2025.
| VE network/Immunocompromise status/ COVID-19 vaccination dosage pattern | COVID-19 case-patients No. (col %) | COVID-19 control patients No. (col %) | Median interval since last dose for vaccinated, days (IQR) | VE %* (95% CI) |
|---|---|---|---|---|
|
VISION, immunocompetent
| ||||
|
No 2024–2025 dose† (Ref)
|
2,016 (90) |
19,198 (80) |
775 (357–1,084) |
Ref
|
|
Received 2024–2025 dose
| ||||
| 7–119 days earlier |
232 (10) |
4,773 (20) |
53 (30–77) |
45 (36–53)
|
| 7–59 days earlier |
129 (6) |
2,759 (12) |
33 (20–46) |
42 (30–52)
|
| 60–119 days earlier |
103 (5) |
2,014 (8) |
81 (70–94) |
48 (36–58)
|
|
VISION, immunocompromised
| ||||
|
No 2024–2025 dose† (Ref)
|
524 (88) |
5,885 (78) |
720 (343–1,064) |
Ref
|
|
Received 2024–2025 dose
| ||||
| 7–119 days earlier |
74 (12) |
1,709 (22) |
53 (31–78) |
40 (21–54)
|
|
IVY network, immunocompetent
| ||||
|
No 2024–2025 dose† (Ref)
|
614 (90) |
1,021 (82) |
—§
|
Ref
|
|
Received 2024–2025 dose
| ||||
| 7–119 days earlier |
69 (10) |
225 (18) |
60 (31–85) |
46 (26–60)
|
| 7–59 days earlier |
41 (6) |
105 (9) |
31 (20–45) |
42 (14–61)
|
| 60–119 days earlier | 28 (4) | 120 (11) | 85 (72–98) | 47 (17–67) |
Abbreviations: Ref = referent group; VE = vaccine effectiveness; VISION = Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network; IVY = Investigating Respiratory Viruses in the Acutely Ill.
* VE was calculated by comparing the odds of 2024–2025 COVID-19 vaccination in case-patients and control patients using the equation: (1 − adjusted odds ratio) x 100%. Odds ratios were estimated by multivariable logistic regression. For VISION, the odds ratio was adjusted for age, sex, race and ethnicity, calendar day, and geographic region. For IVY, the odds ratio was adjusted for age, sex, race and ethnicity, geographic region (U.S. Department of Health and Human Services region), and calendar time (biweekly intervals).
† The “no 2024–2025 dose” group included all eligible persons who did not receive a 2024–2025 COVID-19 vaccine dose, regardless of number of previous COVID-19 vaccine doses (if any) received.
§ Median interval from last dose for persons who received previous doses of COVID-19 vaccine but did not receive a 2024–2025 COVID-19 vaccine dose was not available in the IVY network.